Human Microbiome Market

Global Human Microbiome Market Overview

The global human microbiome market, valued at USD 0.63 billion in 2025, is projected to reach USD 0.85 billion in 2026 and USD 3.27 billion by 2035, with a CAGR of 16% during the forecast period 2026 to 2035.

To learn more about this report, request a free sample copy

The human microbiome comprises the diverse community of microorganisms, including bacteria, archaea, viruses and fungi, that reside in various parts of the human body, such as the skin, gut, mouth and other tissues. The exploration of the human microbiome diversity can be traced back to the 1680s, when Antonie van Leewenhoek compared his oral and fecal microbiota samples.

The current human microbiome landscape is highly dynamic, with research highlighting its essential role in immunity, metabolism, and disorders such as cancer, inflammatory diseases, and even neurodegenerative conditions.

The US FDA has approved two fecal microbiota therapeutics for the prevention of recurrent C. difficile infection (rCDI). Notably, in November 2022, REBYOTA (developed by Ferring Pharmaceutical) was the first human microbiome therapeutic to receive approval, followed by the approval of orally administered VOWST (developed by Seres Therapeutics) in April 2023. It is worth highlighting that the commercial success of VOWST has been bolstered by Nestlé Health Science’s acquisition of its US and global rights in June 2024.

Considering the ongoing innovations in DNA sequencing, bioinformatics and analytical tools to enable a deeper understanding of human microbiome in human health and diseases, we believe that the domain is likely to witness double-digit market growth in the foreseen future.

Recent Developments in Human Microbiome Market

Several recent developments have taken place in the field of human microbiome, and we have outlined some of these below. These developments, even if they arose after our market report’s release, support the overall human microbiome market trends detailed in our analysis.

• In August 2025, Snipr Biome secured € 35 million in series B venture financing to support the development of a CRISPR-Cas therapy specifically targeting infections caused by Pseudomonas aeruginosa in people with cystic fibrosis.

• In August 2025, Alveolus Bio raised $ 2 million in private placement financing to accelerate the clinical advancement of its resMIT (respiratory microbiota-based inhaled therapeutics) platform. This novel platform enables targeted delivery of inhaled therapies directly to the lungs, addressing unmet needs in diseases such as COPD, bronchopulmonary dysplasia (BPD), and pulmonary fibrosis.

• In July 2025, MaaT Pharma entered into an agreement with Clinigen for commercialization and distribution of Xervyteg® (MaaT013), its first in class therapeutic candidate for the treatment of acute Graft-versus-Host Disease.

• In May 2025, IUCN Species Survival Commission (SSC) announced a conference to bring together the conservation and microbial research communities to underline the importance of microbes in human health, food production, global nutrient cycles, greenhouse gas exchange and disease dynamics.

Industry Experts on Human Microbiome Industry Outlook

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes detailed transcripts of interviews conducted with the following individuals:

• Former Senior Manager, Corporate Development, Mid-Sized Company, UK
• Co-founder and Chairman, Small Company, US
• Chief Executive Officer, Small Company, US
• Senior Scientist, Large Company, US
• President, Small Company, Taiwan
• Vice President, Business Development, Small Company, US
• Chief Business Officer, Mid-sized Company, Israel
• Former Vice President, Sales and Business Development, Small Company, US
• Co-founder and Chief Executive Officer, Small Company, Belgium
• Co-founder and Chief Executive Officer, Small Company, US
• Co-founder and Chief Executive Officer, Small Company, US
• Ex-Co-founder and Vice President of Innovation, Mid-sized Company, US
• Vice President & Chief Operating Officer, Small Company, US
• Former Vice President, Operations, Mid-sized Company, US
• Former President and Chief Executive Officer, Small Company, US
• Former Chief Scientific Officer and Vice President, Research, Small Company, US
• Former Chief Strategy Officer, Small Company, France

Human microbiome domain will mark a turning point in 2025. Chief Executive Officer of a small organization in US states, "Currently the market for microbiome sequencing services is likely to be around USD 1 billion; of which, 50-60% of the share is captured by the diagnostics segment and the rest by the research segment."

Human Microbiome Market Segmentation Insights

The market research report presents an in-depth analysis of the market, including various human microbiome therapeutics, diagnostics and fecal microbiota therapy (FMT) developers. It also features the likely distribution across various segments, such as type of product, type of biologic, route of administration, drug formulation, target indication, target therapeutic area and geographical regions.

The global human microbiome market is likely to grow significantly, owing to the increasing awareness of the impact of microbiome on overall health and well-being, expanding clinical pipelines for microbiome therapies and continuous advancements in microbiome metabolomics industry. However, recently the market has seen some setbacks owing to high research and development costs, coupled with the complexity in clinical trials and stringent regulatory requirements. Moreover, ethical considerations surrounding microbiome manipulation and the potential unintended consequences also pose challenges to market expansion.

Owing to the growing research and development efforts behind human microbiome-based diagnostics and therapeutics, the field has seen significant traction. Further, based on the positive outcomes from early-stage clinical trials, we believe that the global human microbiome market is likely to grow at a steady rate during the forecast period.

Human Microbiome Market Share Insights

Market Share by Type of Product: Diagnostics Segment Holds the Largest Share

• In 2025, the diagnostics segment occupies the highest market share (~45%), as per human microbiome market report, owing to the increasing adoption of microbiome-based diagnostic tests for the early screening of various indications, such as metabolic disorders and oncological disorders.
• It is worth mentioning that therapeutics segment is likely to witness a significant growth rate of 32%, during the forecast period. This is due to the increased research and development in personalized therapies, the effectiveness of existing treatments like Fecal Microbiota Transplantation (FMT) for certain conditions and the strong pipeline of novel drugs and therapies under development.

Human Microbiome-based Therapeutics Market Share Insights

Market Share by Type of Biologic: Live Biotherapeutics Segment Holds the Largest Market Share

• In 2025, the live biotherapeutics segment occupies the entire human microbiome market share (for therapeutics) as a result of the increasing adoption of microbiome-based therapies for the treatment of various disorders, such as gastrointestinal disorders, metabolic disorders and oncological disorders.
• It is worth mentioning that others segment (including phage biologics, vaccines and other antibodies) is likely to witness a significant growth rate with a CAGR of 64%, during the forecast period, 2026-2035.

Market Share by Route of Administration: Oral Route Segment Holds the Largest Revenue

• In 2025, the oral route occupies the highest market share (55%) of human microbiome therapeutics market. It is worth noting that the therapies administered via oral route are likely to witness a substantial CAGR of 38% during the forecast period.
• This is due to safety, convenience and the potential for direct therapeutic intervention within the oral cavity to produce desired systemic effects.

Market Share by Drug Formulation: Suspension Segment to Grow at a Higher CAGR

• Among the various segments, the capsule segment occupies the highest human microbiome therapeutics market share (55%) in 2025. This is due to the robust clinical trial pipeline of microbiome-based therapies in the capsule formulation.
• It is worth noting that the market for suspension segment is likely to grow at a relatively higher CAGR (38%), during the forecast period. This is due to its ability to maintain the viability and stability of live microbial formulations, facilitate easy dosage adjustments, and its long history of use for diverse therapeutic purposes.

Market Share by Target Indication: Clostridium Difficile Infection Segment Dominance

• In 2025, the clostridium difficile infection segment occupies the entire human microbiome therapeutics market size. This is a result of increasing prevalence and severity of clostridium difficile infections along with the well-established association between antibiotic-induced gut dysbiosis and the infection.
• Further, the market for therapies targeting acute graft versus host disease is likely to grow at a relatively higher CAGR (35%), during the period 2027-2035. This is due to the anticipated approval of MaaT013 (Xervyteg®), a first-in-class microbiota-based therapy developed to address a critical unmet need in patients with GI-involved acute graft versus host disease, where current survival rates are alarmingly low and no other approved treatment is available.

Market Share by Target Therapeutic Area: Infectious Disorders Segment Dominates the Market

• In 2025, the infectious diseases segment occupies the entire human microbiome therapeutics market size (with a share of 100%) and this trend is unlikely to change in the future. This is due to its direct role in immune function and pathogen defense, and the proven success of microbiome-based therapies like in treating infections like recurrent Clostridium difficile infections.
• It is worth mentioning that the rare disorders segment is likely to grow at a relatively higher CAGR (35%), during the period 2027-2035. Notable examples of microbiome-based therapies targeting rare disorders include SFA003 (Bullous Pemphigoid), MaaT013 (acute graft versus host disease) and BB128 (orphan disease).

Market Share by Geographical Regions: North America with Highest Revenue

• According to our projections, North America is likely to capture the majority (95%) of the human microbiome therapeutics market share in 2025, as the advanced healthcare infrastructure in North America enables developers to conduct a large number of clinical trials, in order to meet the regulatory guidelines of the approval bodies.
• It is worth highlighting that the market in Europe is likely to grow at a relatively higher CAGR (75%), during the period 2025-2032. This growth is driven by MaaT Pharma's recent submission of the Marketing Authorization Application (MAA) for MaaT013, branded as Xervyteg®, to the European Medicines Agency (EMA), which marks a significant breakthrough in the field of microbiota therapeutics and hematology.

Human Microbiome Diagnostics Market Share Insights

Market Share by Target Indication: Diabetes Mellitus Segment With the Largest Share

• In 2025, the diabetes mellitus segment occupies the highest share of human microbiome diagnostics market size (with a share of 46%) and this trend is unlikely to change in the future. This is due to the ability of microbiome-based diagnostic tests to screen and analyze gut microbial imbalances associated with diabetes, helping clinicians to tailor interventions such as targeted probiotics or dietary modifications to improve patient outcomes.
• Further, the market for colorectal cancer segment is likely to grow at a relatively higher CAGR (7%), during the forecast period. This is a result of ongoing advancements in microbiome research which has revealed strong association between gut microbiota imbalance and colorectal cancer. This growing body of evidence makes microbiome diagnostics a promising and non-invasive approach for early CRC detection.

Market Share by Target Therapeutic Area: Gastrointestinal Disorders Segment Holds the Largest Revenue

• In 2025, the gastrointestinal disorders segment occupies the highest share of human microbiome diagnostics market size (with a share of 51%) and this trend is unlikely to change in the future, owing to the increasing recognition of the microbiome’s role on the pathology of gastrointestinal disorders.
• It is worth mentioning that the oncological disorders segment is likely to grow at a relatively higher CAGR (7%), during the forecast period. This is due to the growing understanding of its role in treatment of cancer initiation and progression coupled with the demand for personalized, non-invasive diagnostics and precision medicine in oncology.

Market Share by Geographical Regions: North America Holds the Dominance

• As per our human microbiome diagnostics market forecast, North America is likely to capture the majority (47%) of market share in 2025. Furthermore, the market in North America is expected to grow at a CAGR of 5% during the forecast period.
• This is due to the evolving regulatory framework for microbiome-based diagnostics in North America, which has significantly contributed to the rise in approvals and market growth in this region. Notable examples of approved microbiome-based diagnostic tests include, Evvy Vaginal Health Test, Oncobiota™, GutID™ and Kean Gut+.

Human Microbiome Fecal Microbiota Therapy Market Share Insights

North America Human Microbiome Market

• According to our projections, North America is likely to capture the majority (~95%) of the human microbiome fecal microbiota therapies market size in 2025. This is due to the rising prevalence of antibiotic-resistant infections and gut-related disorders, such as inflammatory bowel diseases. Further, technological advancements in standardized fecal donor screening, novel delivery formats (such as encapsulated microbiota) and a supportive regulatory environment is further accelerating market growth,
• It is worth mentioning that the market in Europe is likely to grow at a relatively higher CAGR (3%), during the forecast period, owing to the rise in public and institutional funding to encourage innovation and expansion in this transformative domain.

Human Microbiome Market Key Takeaways

Human Microbiome Market Competitive Landscape

The market report highlights the number of stakeholders engaged in this rapidly emerging segment of the healthcare market. Key takeaways of the market report have been briefly discussed below.

Competitive Landscape: Human Microbiome Therapeutics Market Analysis

The market landscape is characterized by the presence of around 55 human microbiome therapeutic developers (large, mid-sized and small companies). Of these, 45% of the companies have been established post-2015, indicating the growing interest of stakeholders in this domain. Notable examples of such companies (established post-2017, in alphabetical order) include Alveolus Bio, Armata Pharmaceuticals, BiomeBank, FREYA, Holobiome, mbiomics, Microba, Microbiomik and Notitia Biotechnologies.

It is worth noting that the current pipeline analysis shows that ~35% of the human microbiome therapeutics are currently in preclinical stages of development, with 51% of therapeutics being evaluated in different clinical stages. Further, majority of the therapeutics are administered via oral route, owing to the ease of administration.

Competitive Landscape: Human Microbiome Diagnostics Market Analysis

The current landscape presents 75 well-established players and new entrants that possess technical expertise to develop different types of microbiome-based diagnostic tests. Further, the landscape is well fragmented, featuring players headquartered across different regions.

It is worth noting that majority (41%) of the developers are headquartered in Europe, owing to the rising research initiatives and substantial investments made by both public and private investors in the region. Notably, 54% of the microbiome-based diagnostic developers utilize next generation sequencing and metagenomic technologies, followed by PCR techniques (~35%).

Competitive Landscape: Human Microbiome Fecal Microbiota Therapies Market Analysis

The current market landscape features more than ten companies having the required capabilities to offer fecal microbiota therapies. Of these, 27% of the companies have been established post-2015, indicating the presence of well-established players in this domain.

It is worth noting that 50% of the fecal microbiota therapies are in clinical stages of development (phase II and phase I). Further, majority of the therapies (27%) are being used for the treatment or prevention of infectious diseases, followed by digestive and gastrointestinal disorders.

Human Microbiome Market Analysis: Global Market to Grow at Double-Digit CAGR

The global human microbiome market size is likely to be worth $ 0.63 billion in 2025 and will reach $ 3.27 billion by 2035. The global market highlights distribution into oral route and rectal route, in terms of route of administration. In 2025, the oral route segment dominates the market and holds 55% of the market share, as oral route offers significant advantages in terms of convenience, patient comfort and scalability compared to traditional delivery methods like colonoscopy or enema.

Further, the market size for oral route segment is likely to grow at a relatively higher CAGR of 38% during the forecast period.

Regional Analysis: Which Region Holds the Largest Share of the Human Microbiome Therapeutics Market?

North America is Leading the Human Microbiome Therapeutics Industry

North American companies are likely to dominate the global human microbiome therapeutics market in 2035, owing to the robust research and development activities, coupled with increasing adoption of microbiome-based diagnostics and therapies for a wide range of indications.

Latin America: An Emerging Growth Spot in the Human Microbiome Therapeutics Market

The market in Latin America is likely to grow at a relatively high CAGR (84%), during the period 2032-2035. This is a result of increased healthcare spending and government initiatives to improve healthcare infrastructure, along with a surge in number of clinical trials for microbiome-based therapies, in this region.

Human Microbiome Market Growth Drivers and Market Challenges

Advancements in Sequencing and Bioinformatics Technologies as a Key Driver for the Human Microbiome Market

Technological advancements, such as sequencing by synthesis are major growth drivers for the human microbiome market as they have significantly improved the ability to analyze and understand complex microbial communities with greater speed, accuracy and depth. Further, the rising demand for personalized medicine, expanding applications in preventive healthcare and growing consumer awareness about gut health tests and impact of probiotics on human microbiome market is a significantly contributor.

The human microbiome is a transformative domain in medicine and health as advanced data analytics and integrative multi-omics approaches are now unlocking new insights. Consequently, enabling more accurate diagnosis and the development of targeted therapies including engineered probiotics, fecal transplants and microbiome-based drugs.

Additionally, the indications targeted by microbiome-based therapies are rapidly expanding, with several promising candidates progressing through late-stage clinical trials, particularly Phase III. For example, MaaT Pharma’s MaaT013 is being developed for acute graft-versus-host disease (aGvHD) to improve outcomes in steroid-refractory patients. This expansion is further supported by strong interest and funding from major pharmaceutical companies and biotech investors who recognize the potential of microbiome interventions to offer novel, targeted and potentially safer treatment options compared to conventional therapies.

What are the Key Challenges Facing the Human Microbiome Market?

Despite their several benefits, the human microbiome market faces several challenges. One of the most significant issues is the discontinuation of microbiome-based therapies, reflecting the complexity of translating microbiome science into effective treatments. For instance, Finch Therapeutics recently announced the discontinuation of their oral microbiome therapy CP101 after it failed to meet primary endpoints in a Phase III trial for Clostridium difficile infection, illustrating the clinical and biological hurdles in this field.

Further, the regulatory complexities and lack of standardized guidelines for microbiome therapeutics and diagnostics create barriers across countries, resulting in delayed market approvals, increased costs and complicated market entry. Additionally, the high cost of microbiome biologics such as VOWST further complicates market growth. Such financial and developmental barriers underscore the need for advancements in scalable production, clinical validation and cost containment strategies to sustain growth and accessibility in the human microbiome market.

Human Microbiome Market Trends 2025

Rising Partnership and Collaborations Amongst the Industry Stakeholders to Foster Progress and Innovation in Expanding their Capabilities

Human microbiome companies have forged several partnerships with other stakeholders to enhance their products portfolios, significantly influencing innovation and global reach. For human microbiome diagnostics and therapies developers, research and development agreements have emerged as the most popular engagement model. Notably, in the last three years, companies based in North America have inked more than 30% of these partnerships to strengthen their human microbiome capabilities.

Funding Analysis: Human microbiome-based Diagnostic and Therapies Developers have Experienced Investment Growth in the Past Three Years

Over the years, monetary assistance from venture capitalists and funding schemes of various public and private organizations, along with assistance from regulatory authorities, have allowed start-ups / small companies to progress their research and development efforts in the human microbiome domain.

Notably, in the past three years, human microbiome companies have raised a total amount of over USD 1,230 billion to enhance their product portfolio. Further, it is worth mentioning that Armata pharmaceuticals emerged as the most prominent player in this domain, having raised funding across private placement, grant, and debt financing.

Clinical Trials Landscape: Europe is the Hub for Clinical Trials Evaluating Fecal Microbiota Therapy

Close to 205 clinical trials investigating various fecal microbiota therapies have been reported since 2021, indicating the substantial research efforts being made in this industry. Further, over 30% clinical trials have been registered in 2024, demonstrating rising awareness amongst researchers and drug developers to develop advanced fecal microbiota therapies for the treatment of various indications.

Additionally, majority of the overall clinical trials in the fecal microbiota therapies domain have already been completed / are under progress in Europe, followed by Asia-Pacific. The increasing number of clinical trials is as a result of the lower infrastructure cost and large patient population for FMT procedures.

Technological Advancements to Fuel Innovation and Drive Efficiency

Technological advancements in human microbiome research, particularly in next generation sequencing services sector, have revolutionized microbiome analysis by enabling high-throughput, accurate and cost-effective sequencing of microbial DNA from diverse types of microbiome. These technologies allow comprehensive profiling of complex microbial communities, even those with unculturable organisms, leading to deeper insights into their roles in health and disease progression.

Additionally, the application of long-read sequencing platforms further offers high accuracy, better resolution and less number of errors. Coupled with powerful bioinformatics and AI-driven data analysis tools, these advancements accelerate discovery, enable personalized diagnostics and therapeutics and reduce turnaround time.

Human Microbiome Market Forecast: Report Attributes

Key Report Attributes	Details
Historical Trend	Since 2022
Forecast Period	Till 2035
Market Size 2026	$0.85 Billion
Market Size 2035	$3.27 Billion
CAGR (Till 2035)	16%
Type of Product	Therapeutics Diagnostics Fecal Microbiota Therapies
Type of Biologic	Live Biotherapeutics Others
Route of Administration	Oral Route Rectal Route
Drug Formulation	Capsule Suspension Enema Powder
Target Indication	Clostridium Difficile Infection Necrotizing Enterocolitis Irritable Bowel Syndrome Acute Graft Versus Host Disease Diabetes Mellitus Irritable Bowel Disease Colorectal Cancer
Target Therapeutic Area	Infectious Disorders Gastrointestinal Disorders Rare Disorders Metabolic Disorders Oncological Disorders
Geographical Regions	North America Europe Asia-Pacific Latin America Middle East and North Africa
Market in North America	US Canada
Market in Europe	Germany France Italy UK Spain Rest of the Europe
Market in Asia-Pacific	Australia China India Japan
Market in Latin America	Brazil
Market in Middle East and North Africa	Israel Saudi Arabia
Excel Data Packs (Complimentary)	Human Microbiome Therapeutics Market Overview Human Microbiome Diagnostics Market Overview Human Microbiome Fecal Microbiota Therapies Market Overview Fecal Microbiota Therapies Clinical Trial Analysis Start-up Health Indexing Funding and Investments Partnerships and Collaborations Human Microbiome Therapeutics Market Forecast Human Microbiome Diagnostics Market Forecast Human Microbiome Fecal Microbiota Therapies Market Forecast
Key Players	Becton, Dickinson and Company Biome Diagnostics Ferring Pharmaceuticals GoodGut Infant Bacterial Therapeutics MaaT Pharma Microbiomik NutriPATH Seres Therapeutics Tiny Health OxThera Vedanta Bisociences Zybio (A complete list of around 135 companies is available in the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization

Frequently Asked Questions

Question 1: When did the Human Microbiome Project end?

Answer: The Human Microbiome Project (HMP) officially ended in 2016. It was a United States National Institutes of Health (NIH) research initiative launched in 2007 that ran for about a decade and made several landmark findings in generating comprehensive datasets to advance understanding of the human microbiome.

Question 2: What regulatory frameworks affect the approval and marketing of human microbiome products globally?

Answer: The regulatory frameworks governing human microbiome products vary globally but their core focus is on ensuring safety, quality and efficacy while addressing the unique complexities of live biological materials. In the United States, the FDA regulates live biotherapeutic products (LBPs), whereas in European Union, microbiome-based products fall under biological medicinal products regulated by Directive 2001/83/EC.

Question 3: How is the market expected to evolve regarding diagnostic tools and pharma CDMO services?

Answer: The human microbiome industry is experiencing remarkable growth, driven by technological advancements in diagnostic tools and increased outsourcing to pharma CDMO services, with key sectors advancing at double-digit CAGR till 2035.

Question 4: How big is the human microbiome market?

Answer: The market is likely to be worth USD 0.85 billion in 2026.

Question 5: What forecasted CAGR and revenue figures can stakeholders expect in the human microbiome market by 2035?

Answer: The market is likely to grow at CAGR of 16% during the forecast period, till 2035.

Question 6: What is the human microbiome market global forecast for 2035?

Answer: The global market size is likely to be worth USD 3.27 billion by 2035.

Question 7: Which key factors are driving growth in the human microbiome market across pharma and healthcare sectors?

Answer: Significant technological advancements in microbiome sequencing platforms, rising emphasis on personalized medicine, coupled with increasing awareness of the role of microbiome in various health conditions.

Question 8: What are the primary challenges and barriers currently impacting the development and commercialization of microbiome-based therapeutics?

Answer: Complexity in conducting robust and reliable clinical trials, lack of standardized and validated analytical methods for accurately characterizing microbiome composition are the primary challenges faced during the development and commercialization of microbiome-based therapeutics.

Question 9: How is regional market growth distributed, particularly in North America, Europe, and Asia-Pacific?

Answer: North America holds more than 55% share in the current market.

Question 10: How is the competitive landscape shaping up in the human microbiome market, and who are the leading companies?

Answer: The competitive landscape is rapidly evolving, characterized by increasing strategic partnerships, investments and clinical trials. Notable examples of key players include Seres Therapeutics, Ferring Pharmaceuticals, BiomeBank, Genetic Analysis and Rebiotix.